Cyclin e1

Human HCC cell lines (HepG2, PLC/PRF/5, Bel-7402, SMMC-7721, HBXF-344, SNU-387, and SNU-449), human pancreatic cancer cell lines (PANC 504, SW1990, MIAPaCa-2, PANC-1), and human embryo liver cell line L02 were grown as described [27 (link), 28 (link)] in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS; Hyclone, Logan, UT). The cells were split to low density (30% confluence) for overnight culture and were then treated with 2 μM of 5-AZA (Sigma-Aldrich) for 96 h with the medium exchanged every 24 h or with 4 μM of trichostatin A (TSA) (Sigma-Aldrich) for 24 h. For combined treatment, the cells were initially exposed to 5-AZA for 72 h followed by 5-AZA and TSA for 24 h.
The primary antibodies were used against the following proteins for Western blot: PRSS3 from R&D Systems (Cat. no.: MAB3710); p-MEK1/2 from Cell Signaling Technology (Cat. no.: 9121); cyclin D1 from Proteintech Group, Inc. (Cat. no.: 60186–1-Ig); and cyclin-dependent kinase 2 (CDK2), CDK4, cyclin E1, matrix metallopeptidase 2 (MMP2), MEK1/2, ERK1/2, p-ERK1/2, and β-actin from Bioworld Technology, Inc. (Cat. nos.: BS1050, MB0027, BS1085, BS1236, BS3599, BS1112, BS5016, and BS6007M, respectively).
All oligonucleotide sequences are listed in Supplementary Table 1.